Opinions, ideas, and research from NPLB
When Simpler isn't Better
A case for generalizing cost-effectiveness math to avoid undervaluing medicines
CMS Rule to Lower Maximum Out-of-Pocket Costs by $400 Will Help Patients, More Reductions Needed
NPLB welcomed key provisions in CMS Notice of Benefit and Payment Parameters for 2022 Final Rule
NPLB Applauds Growing Momentum for Insurance Reforms that Lower Out-of-Pocket Costs for Patients
Prioritizing reforms such as drug pricing and access that help patients is essential.
Patient Out-of-Pocket Costs Continue to Climb While Insurers are Covering Fewer Drugs
Despite Reductions in Pharmaceutical Manufacturer Net Drug Prices
NPLB Applauds President’s Expansion of Affordable Healthcare
More Americans Helped, More Still to be Done
How To Kill The Conversation That Makes Innovation Possible
A short analysis
Feel free to reach out with questions, concerns, or comments.